Peijia Medical Ltd. (HK:9996) has released an update.
Peijia Medical Limited has announced the acquisition of its licensing partner, JenaValve Technology, Inc., by Edwards Lifesciences Corporation, maintaining Peijia’s exclusive rights to develop and commercialize the TaurusTrio™ Transcatheter Heart Valve System in Greater China. The merger does not affect Peijia’s ongoing clinical trial in China or its rights to the licensed technology, with the company expressing confidence in the technology’s prospects for treating heart conditions. Investors are advised to exercise caution when dealing in Peijia Medical’s shares as the development and market success of TaurusTrio™ is not guaranteed.
For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.
